Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.47 |
| ▸ | LPL | P06858 | 10/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12390740 | 0.89 | LIPG (0.56) | LIPGLPLPRMT5WDR77PDGFRB | |
| SCHEMBL19107131 | 0.88 | LIPG (0.53) | LIPGLPLPRMT5WDR77PDGFRB | |
| SCHEMBL19107129 | 0.88 | LIPG (0.53) | LIPGLPLPRMT5WDR77PDGFRB | |
| SCHEMBL20232183 | 0.88 | LPL (0.48) | LIPGLPLPRMT5WDR77P4HB | |
| SCHEMBL29507270 | 0.88 | LPL (0.48) | LIPGLPLPRMT5WDR77P4HB | |
| SCHEMBL25799128 | 0.85 | LIPG (0.62) | LIPGLPLPDGFRBKDRP4HB | |
| SCHEMBL24910026 | 0.84 | LIPE (0.39) | LIPGLPL | |
| SCHEMBL27403487 | 0.84 | LPL (0.45) | LIPGLPLDGAT1 | |
| SCHEMBL16641537 | 0.83 | LIPG (0.44) | LIPGLPLPRMT5WDR77PDGFRB | |
| SCHEMBL12560678 | 0.83 | LPL (0.63) | LIPGLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11024815-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| EP-3254317-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| WO-2016124304-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11024815-B2 | Metal complexes | EXOC4, EXOC3, TIMCC | LIPG 4459/4885LPL 4682/4885PRMT5 2407/4885 |
| US-20180026209-A1 | Metal Complexes | AP3M1, AP2M1, SOD1 | LIPG 3693/4885LPL 3416/4885PRMT5 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.